Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04072952 | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer(mBC) | completed | Phase 1 / Phase 2 | 219 | Arvinas Estrogen Receptor, Inc.INDUSTRY | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT07396766 | Dissemination of BREASTChoice AIM1-B(BREASTChoice) | completed | N/A | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00006421 | Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study | completed | — | 200 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00043472 | Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk | completed | — | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00475761 | Breast Mammogram and Tissue Study | completed | — | 466 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03734029 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | completed | Phase 3 | 557 | Daiichi SankyoINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT04573231 | Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT05880160 | Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction(HER-SAFE) | completed | N/A | 90 | University College, LondonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02188745 | ER Reactivation Therapy for Breast Cancer(POLLY) | completed | Phase 2 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT03697577 | CDK and Body Composition Study | completed | — | 30 | Montefiore Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05498155 | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer(OlympiaN) | completed | Phase 2 | 50 | AstraZenecaINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT05607849 | Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid(DEDICACES2) | completed | N/A | 20,000 | Nantes University HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05913713 | HIIT Following Breast Cancer Chemotherapy | completed | N/A | 37 | University of FloridaOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842055 | AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma | completed | — | 3,648 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842068 | Artificial Intelligence (AI) - Based Models for Biomarkers Prediction | completed | — | 3,648 | Hellenic Cooperative Oncology GroupOTHER | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07842614 | Effect of a Brassicaceae-Enriched Diet on Menopausal Symptoms in Women With Breast Cancer Receiving Antiestrogen Therapy(BRASSICA) | completed | N/A | 81 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07843121 | Supervised Exercise in Women With Breast Cancer | completed | N/A | 16 | University of ExtremaduraOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02390427 | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | completed | Phase 1 | 68 | Nancy Lin, MDOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02860000 | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | completed | Phase 2 | 96 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03220893 | Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue | completed | N/A | 3,023 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04224272 | Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant | completed | Phase 2 | 51 | Jazz PharmaceuticalsINDUSTRY | 3 | Sep 24, 2026 | clinicaltrials |
| NCT05444998 | Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer | completed | Phase 2 | 20 | Xijing HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07820228 | Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy | completed | — | 3,648 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03387553 | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | completed | Early Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03357120 | Circulating Tumor DNA After Neoadjuvant Chemotherapy(ALIENOR) | completed | N/A | 120 | Institut BergoniéOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT05812040 | Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge | completed | N/A | 134 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06137833 | Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy | completed | N/A | 92 | Pharmanutra S.p.a.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07338721 | Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? | completed | — | 100 | Antalya Training and Research HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829900 | First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer | completed | — | 2,250 | Xin LiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831460 | Horse-assisted Interventions in an Oncological Centre(ISACCO) | completed | N/A | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06846060 | A Mindfulness-Based Self-Compassion Program | completed | N/A | 64 | Nevsehir Haci Bektas Veli UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828925 | Selective Axillary Dissection After Neoadjuvant Chemotherap Yin Patients With Lymphnode-positive Breast Cancer(CLYP) | completed | — | 105 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT00417495 | Sentinel Lymph Node Technique in Multifocal Breast Cancer(IGASSU) | completed | Phase 2 | 216 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00904410 | Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET(CHIMTEP) | completed | Phase 4 | 63 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00911911 | Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy(SPAM) | completed | N/A | 66 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01658462 | Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer(VAROCE) | completed | Phase 2 | 51 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02281149 | Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy:(TOMOBREAST) | completed | — | 500 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)(PREPARE) | completed | N/A | 792 | Institut BergoniéOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07799909 | Behavioral Activation for Cancer-Related Fatigue After Breast Cancer Surgery | completed | N/A | 114 | Huaidong ChengOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07819045 | Self-Acceptance and Supportive Accountability for Active Living Among Adults Receiving Chemotherapy | completed | N/A | 42 | University of OklahomaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03667612 | Endogenous Mechanisms of Inactivation of the Endothelium Tumor(BreastIls) | completed | — | 70 | Centre Oscar LambretOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05898009 | Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2(CanSeR-OGen) | completed | N/A | 228 | Centre Hospitalier Universitaire de la RéunionOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823751 | The Role of Bisphosphonate and Simvastatin Combination on Therapeutic Response in Breast Cancer With Bone Metastasis Via Dicckopf-1 Pathway | completed | N/A | 35 | Indonesia UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05206331 | CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study | completed | Phase 4 | 2,089 | Margarita Louise ZuleyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820124 | Digital Education for Breast Cancer Screening Beliefs and Prevention Behaviors | completed | N/A | 120 | Gümüşhane UniversıtyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06879678 | Web-Based Exercise for Neuropathy and Quality of Life in Breast Cancer | completed | N/A | 95 | Bilecik Seyh Edebali UniversitesiOTHER | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials